How should kidney function be monitored during Afatinib therapy?

Serum creatinine/eGFR and electrolytes (including magnesium) during early cycles and any diarrhea; Stool frequency and volume status at each contact; Serum magnesium periodically (EGFR-class wasting).

How can kidney injury from Afatinib be prevented?

Early, aggressive antidiarrheal management (e.g., loperamide) per protocol Patient education on hydration and prompt reporting of diarrhea Dose interruption/reduction for severe diarrhea

Who is at higher risk of kidney injury from Afatinib?

Severe or unmanaged diarrhea; Older age and frailty; Pre-existing chronic kidney disease; Concurrent diuretics or other nephrotoxins.

Back to explorer

Printable monograph

EGFR TKI

Afatinib

Gilotrif · AFA

EGFR TKI · approved 2013 · 8 citations · FAERS AKI reporting ROR 2.04 (95% CI 1.67–2.50, 97 AKI reports)

Recent· through 2024

Deeply sourced8/9 · 7 signals

Met: 8 citations
Not met: 12+ references
Met: Accrued over 10+ years (span: 11y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2024
Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

An irreversible pan-ErbB TKI whose main renal risk is dehydration-driven prerenal AKI from severe diarrhea, plus class hypomagnesemia.

MildEGFR TKI

EGFR-mutant metastatic non-small cell lung cancer (including selected uncommon EGFR mutations)Squamous NSCLC after platinum-based chemotherapy

§01

Signature kidney injury

Signature lesion

Prerenal / Hemodynamic AKI

Diarrhea is very common with afatinib (the dominant class toxicity, all-grade in the large majority and grade >=3 in roughly 10-15% in LUX-Lung trials), and the consequent dehydration can precipitate prerenal AKI. Pharmacovigilance data identify afatinib as carrying the strongest renal-failure/AKI signal among EGFR agents, frequently co-reported with diarrhea; trial-based renal incidence is not separately quantified.Source: Crosnier et al., Cancers 2021

Onset & rechallenge

Time to injuryAcute (~1–7 days)

Days to weeks after starting, tracking the onset and severity of diarrhea (often within the first cycles).

Distilled from: “Days to weeks after starting therapy, tracking with the onset and severity of diarrhea (often within the first cycles).”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Prerenal / Hemodynamic AKI#1 · Signaturequalitative — no citable incidence
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Acute Tubular NecrosisSecondaryqualitative — no citable incidence
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Electrolyte DisturbanceSecondaryqualitative — no citable incidence
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

Incidence not quantified

SeverityMild

ReversibilityReversible

Evidence8 citations

Nephron map

Vasculature / Endothelium

Proximal Tubule

Distal Tubule / Collecting Duct

Prerenal / Hemodynamic AKI

Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

§03

Kidney injury

Mechanism of kidney injury

Predominantly a hemodynamic, prerenal injury. Severe secretory diarrhea (a pan-ErbB on-target effect on intestinal chloride secretion) together with reduced oral intake causes volume depletion and renal hypoperfusion; sustained ischemia can progress to acute tubular necrosis. Concurrent gastrointestinal and renal electrolyte losses (hypokalemia, hypomagnesemia—the latter also via the EGFR/TRPM6 distal-tubule mechanism) accompany the toxicity.

Clinical presentation

Rising creatinine with clinical volume depletion in the setting of significant diarrhea; low urine output, concentrated urine with a low fractional excretion of sodium early, and electrolyte derangements (hypomagnesemia, hypokalemia). Improves promptly with rehydration when caught early.

Management

Treat diarrhea promptly and restore volume with oral or intravenous fluids; correct electrolytes including magnesium and potassium. Hold afatinib for severe diarrhea or AKI and resume at a reduced dose after recovery. Most cases resolve with volume repletion once the underlying gastrointestinal toxicity is controlled.Lesion-level management framework

Risk factors

Severe or unmanaged diarrhea
Older age and frailty
Pre-existing chronic kidney disease
Concurrent diuretics or other nephrotoxins

Prevention

Early, aggressive antidiarrheal management (e.g., loperamide) per protocol
Patient education on hydration and prompt reporting of diarrhea
Dose interruption/reduction for severe diarrhea

Anticancer mechanism· how it treats cancer

Irreversible inhibitor of the ErbB family (EGFR/HER1, HER2, HER4) tyrosine kinases, covalently blocking signaling in EGFR-mutant tumors and overcoming some resistance. Used for EGFR-mutant non-small cell lung cancer, including selected uncommon mutations.

Note · The renal signal is largely indirect (volume depletion from diarrhea) rather than a primary nephropathy; afatinib also shares the EGFR-class potential for distal-tubule hypomagnesemia.

§04

Clinical depth

Renal dose adjustment

No initial renal dose reduction for mild-moderate impairment; for severe renal impairment (eGFR ~15-29) a reduced starting dose (30 mg daily) is advised per labeling, with titration as tolerated. The practical priority is holding/reducing for grade >=2-3 diarrhea to prevent prerenal AKI.

Dialyzability & ESKD dosing

Not appreciably dialyzable—highly protein-bound (~95%), lipophilic, with predominantly fecal/biliary excretion and minimal renal clearance; hemodialysis is not expected to remove meaningful amounts.

Differential diagnosis

Separate diarrhea-driven prerenal AKI (volume depletion, low FE-Na, rapid response to fluids) from intrinsic ATN (muddy-brown casts, slower recovery) and from concurrent nephrotoxins. EGFR-class hypomagnesemia (high FE-Mg) is distinguished from GI magnesium loss (low FE-Mg).

Monitoring

Serum creatinine/eGFR and electrolytes (including magnesium) during early cycles and any diarrhea
Stool frequency and volume status at each contact
Serum magnesium periodically (EGFR-class wasting)

Key trials & series

LUX-Lung 3 (Sequist JCO 2013) registrational trial; diarrhea the leading AE
LUX-Lung 2/3/6 pooled uncommon-mutation analysis (Yang Lancet Oncol 2015)
Crosnier Cancers 2021 VigiBase EGFR renal-safety pharmacovigilance

Clinical pearls

Afatinib's kidney risk is mostly the gut: aggressive antidiarrheal care and rehydration prevent prerenal AKI.
Start loperamide at the first loose stool—do not wait for grade 3 diarrhea.
Reduce the starting dose to 30 mg daily in severe renal impairment.
Don't forget magnesium: afatinib adds distal-tubule (EGFR/TRPM6) wasting on top of GI losses.

Beyond the kidney — non-renal toxicities· 3 organ systems

Class-level context for the major non-renal toxicities of the EGFR TKI class.

Dermatologic

Rash, HFS, SJS/TEN, vitiligo

Acneiform rash, paronychia

Gastrointestinal

Diarrhea, colitis, mucositis, perforation

Diarrhea

Pulmonary

Pneumonitis, ILD, effusions, hypertension

Interstitial lung disease (EGFR TKIs)

§05

References

6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

6 references · 2013–2024 · 1 since 2022

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 2

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseB · ModerateA case of crescentic glomerulonephritis induced by afatinib for lung adenocarcinoma.Morita D et al. · CEN Case Rep 2023 · PMID 36180718A patient developed afatinib-induced AKI twice (after starting and after dose escalation) requiring dialysis, with biopsy-proven crescentic glomerulonephritis; the report also notes afatinib's more typical renal injury via diarrhea-driven volume loss and prerenal AKI.CaseC · LimitedAfatinib-Induced Tumor Lysis Syndrome in Pulmonary Adenocarcinoma: A Case Report and Literature Review.Hong G · Medicina (Kaunas) 2023 · PMID 38138247A patient developed oliguric acute kidney injury four days after starting afatinib, diagnosed as afatinib-induced tumor lysis syndrome, the first such reported case in pulmonary adenocarcinoma.

FDA label — boxed warning & renal dosing· renal impairment

Quoted verbatim from this agent's current FDA label (Sep 2026) — not paraphrased or interpreted. Full label on DailyMed .

Renal impairment — from the label

Patients with severe renal impairment have a higher exposure to afatinib than patients with normal renal function. Administer afatinib at a starting dose of 30 mg once daily in patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m 2 as determined by Modification of Diet in Renal Disease formula) [see Dosage and Administration ( 2.4 ), Clinical Pharmacology ( 12.3 ) ]. Adjustments to the starting dose of afatinib are not necessary in patients with mild or moderate renal impairment (eGFR 30 to 89 mL/min /1.73 m 2 ). Afatinib has not been studied in patients with eGFR <15 mL/min/1.73 m 2 or on dialysis.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 6,587 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 3 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Electrolyte Disturbancecorroborated · ROR 2.53 — but the naming terms alone are not disproportionate, so this rests on terms merely consistent with the lesion
Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.
Acute Tubular NecrosisNot measurable in reporting — Reporters cannot reliably name this lesion, so its absence from FAERS is expected and is not evidence against the documented injury.

Electrolyte Disturbance

ROR 2.5395% CI 2.16–2.98· 150 reports

SIADH / Hyponatremia

ROR 2.1895% CI 1.68–2.85· 55 reports

Glomerular Injury / Proteinuria

ROR 1.7595% CI 1.07–2.86· 16 reports

FAERS outcomes & reporting trend· 22.2% of reports w/ death · 31.6% w/ hospitalization

22.2%

Reported with a death outcome

1,464 of 6,587 reports

31.6%

Reported with hospitalization

2,084 of 6,587 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 6 systems · 6,587 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 2.0495% CI 1.67–2.50· 97 AKI reports ·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.

Gastrointestinal

Diarrhoea2,121Nausea486Stomatitis485Vomiting407

Skin

Rash884Dry Skin199Pruritus164Dermatitis Acneiform151Alopecia139

General / constitutional

Fatigue292Asthenia237Weight Decreased207Pyrexia165

Metabolic & electrolyte

Decreased Appetite450Dehydration316

Respiratory

Dyspnoea216Pleural Effusion181Interstitial Lung Disease149

Immune / infection

Pneumonia191

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Afatinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Mobocertinib

Exkivity · EGFR exon20 TKI

Profile

Diarrhea-driven prerenal AKI; QT prolongation.

PREATNLYTE

Mild#1 · 86% phenotype match

Arsenic trioxide

Trisenox · Differentiating agent

Profile

Differentiation syndrome; QT prolongation.

PREATNLYTE

Moderate#2 · 84% phenotype match

Enasidenib

Idhifa · IDH2 inhibitor

Profile

Differentiation syndrome and tumor lysis.

PREATNLYTE

Moderate#3 · 84% phenotype match

Ivosidenib

Tibsovo · IDH1 inhibitor

Profile

Differentiation syndrome → AKI; tumor lysis.

PRELYTEATN

Moderate#4 · 84% phenotype match

Binimetinib

Mektovi · MEK inhibitor

Profile

Creatinine rise; rhabdomyolysis reports.

ATNPRE

Mild#5 · 73% phenotype match

Selumetinib

Koselugo · MEK inhibitor

Profile

Creatinine rise in neurofibromatosis.

PRELYTE

Mild#6 · 73% phenotype match

Compare Afatinib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across EGFR / HER2 inhibitors

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Afatinib’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Afatinib; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 14 clinical records among all 21 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.